The FDA has taken a clear position with Project Optimus in shifting toward more progressive tailored approaches while rejecting antiquated study designs to evolve clinical trial strategies to better align with newer drug classes.
Sirj Goswami, PhD, and Jason Rizzo, MBA
Advertisement
Articles by Sirj Goswami, PhD, and Jason Rizzo, MBA
Advertisement
Latest Updated Articles
Artificial Intelligence Drives Industry Response to Project OptimusFebruary 27th 2024
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Continuous Glucose Monitoring in Diabetes Clinical Trials: Endpoints, Regulatory Guidance, and Operational Best Practices
2
Why So Many Patients From Underrepresented Groups Are Never Asked to Join a Trial
3
What Smaller Biotechs Need to Get Right in Their First APAC Phase III Trial
4
Why APAC Clinical Trial Sites Deserve a Second Look: Q&A with James Cheong, Precision for Medicine
5